27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
NEW YORK, Oct. 17, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Repligen Corporation (NASDAQ:RGEN), SpartanNash Company (NASDAQ:SPTN), AZUL SA (NYSE:AZUL), Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX), Ichor Holdings, Ltd. (NASDAQ:ICHR), and Scorpio Tankers Inc. (NYSE:STNG), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Complimentary Access: Research Reports
Full copies of recently published reports are available to readers at the links below.
RGEN DOWNLOAD: http://MarketSourceResearch.com/register/?so=RGEN
SPTN DOWNLOAD: http://MarketSourceResearch.com/register/?so=SPTN
AZUL DOWNLOAD: http://MarketSourceResearch.com/register/?so=AZUL
PCRX DOWNLOAD: http://MarketSourceResearch.com/register/?so=PCRX
ICHR DOWNLOAD: http://MarketSourceResearch.com/register/?so=ICHR
STNG DOWNLOAD: http://MarketSourceResearch.com/register/?so=STNG
(You may have to copy and paste the link into your browser and hit the [ENTER] key)
The new research reports from Market Source Research, available for free download at the links above, examine Repligen Corporation (NASDAQ:RGEN), SpartanNash Company (NASDAQ:SPTN), AZUL SA (NYSE:AZUL), Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX), Ichor Holdings, Ltd. (NASDAQ:ICHR), and Scorpio Tankers Inc. (NYSE:STNG) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.
-----------------------------------------
Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed October 15th, 2018. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.
-----------------------------------------
REPLIGEN CORPORATION (RGEN) REPORT OVERVIEW
Repligen's Recent Financial Performance
For the three months ended June 30th, 2018 vs June 30th, 2017, Repligen reported revenue of $47.73MM vs $32.46MM (up 47.07%) and analysts estimated basic earnings per share $0.06 vs $0.25 (down 76.00%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Repligen reported revenue of $141.24MM vs $104.54MM (up 35.10%) and analysts estimated basic earnings per share $0.74 vs $0.35 (up 111.43%). Analysts expect earnings to be released on November 8th, 2018. The report will be for the fiscal period ending September 30th, 2018. The reported EPS for the same quarter last year was $0.15. The estimated EPS forecast for the next fiscal year is $0.86 and is expected to report on February 28th, 2019.
To read the full Repligen Corporation (RGEN) report, download it here: http://MarketSourceResearch.com/register/?so=RGEN
-----------------------------------------
SPARTANNASH COMPANY (SPTN) REPORT OVERVIEW
SpartanNash's Recent Financial Performance
For the three months ended June 30th, 2018 vs June 30th, 2017, SpartanNash reported revenue of $1,895.95MM vs $1,856.20MM (up 2.14%) and analysts estimated basic earnings per share $0.49 vs $0.56 (down 12.50%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, SpartanNash reported revenue of $8,128.08MM vs $7,734.60MM (up 5.09%) and analysts estimated basic earnings per share -$1.41 vs $1.52. Analysts expect earnings to be released on November 14th, 2018. The report will be for the fiscal period ending September 30th, 2018. Reported EPS for the same quarter last year was $0.54. The estimated EPS forecast for the next fiscal year is $2.19 and is expected to report on February 20th, 2019.
To read the full SpartanNash Company (SPTN) report, download it here: http://MarketSourceResearch.com/register/?so=SPTN
-----------------------------------------
AZUL SA (AZUL) REPORT OVERVIEW
AZUL SA's Recent Financial Performance
For the three months ended June 30th, 2018 vs June 30th, 2017, AZUL SA reported revenue of $561.58MM vs $537.15MM (up 4.55%) and analysts estimated basic earnings per share -$0.11 vs -$0.09. For the twelve months ended December 31st, 2017 vs December 31st, 2016, AZUL SA reported revenue of $2,439.67MM vs $1,912.26MM (up 27.58%) and analysts estimated basic earnings per share $1.60 vs -$0.00. Analysts expect earnings to be released on November 8th, 2018. The report will be for the fiscal period ending September 30th, 2018. Reported EPS for the same quarter last year was $0.59. The estimated EPS forecast for the next fiscal year is $1.88 and is expected to report on March 14th, 2019.
To read the full AZUL SA (AZUL) report, download it here: http://MarketSourceResearch.com/register/?so=AZUL
-----------------------------------------
PACIRA PHARMACEUTICALS, INC. (PCRX) REPORT OVERVIEW
Buy at this blue line for a shot at trading profitably
There are so many indicators out there on when to buy and sell. Nic uses none. He looks at a chart and buys when a stock “pushes” off this blue line. What blue line? Find out on the next page. It’ll change how you make money from stocks. Click here for the details.
Pacira Pharmaceuticals' Recent Financial Performance
For the three months ended June 30th, 2018 vs June 30th, 2017, Pacira Pharmaceuticals reported revenue of $84.11MM vs $70.93MM (up 18.57%) and basic earnings per share $0.06 vs -$0.49. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Pacira Pharmaceuticals reported revenue of $286.63MM vs $276.37MM (up 3.71%) and analysts estimated basic earnings per share -$1.07 vs -$1.02. Analysts expect earnings to be released on November 14th, 2018. The report will be for the fiscal period ending September 30th, 2018. The reported EPS for the same quarter last year was -$0.11. The estimated EPS forecast for the next fiscal year is -$0.35 and is expected to report on February 27th, 2019.
To read the full Pacira Pharmaceuticals, Inc. (PCRX) report, download it here: http://MarketSourceResearch.com/register/?so=PCRX
-----------------------------------------
ICHOR HOLDINGS, LTD. (ICHR) REPORT OVERVIEW
Ichor's Recent Financial Performance
For the three months ended June 30th, 2018 vs June 30th, 2017, Ichor reported revenue of $248.97MM vs $159.73MM (up 55.87%) and analysts estimated basic earnings per share $1.09 vs $0.40 (up 172.50%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Ichor reported revenue of $655.89MM vs $405.75MM (up 61.65%) and analysts estimated basic earnings per share $2.25 vs $0.92 (up 144.57%). Analysts expect earnings to be released on November 6th, 2018. The report will be for the fiscal period ending September 30th, 2018. The reported EPS for the same quarter last year was $0.60. The estimated EPS forecast for the next fiscal year is $3.83 and is expected to report on February 6th, 2019.
To read the full Ichor Holdings, Ltd. (ICHR) report, download it here: http://MarketSourceResearch.com/register/?so=ICHR
-----------------------------------------
SCORPIO TANKERS INC. (STNG) REPORT OVERVIEW
Scorpio Tankers' Recent Financial Performance
For the three months ended June 30th, 2018 vs June 30th, 2017, Scorpio Tankers reported revenue of $141.80MM vs $118.42MM (up 19.74%) and analysts estimated basic earnings per share -$0.22 vs -$0.38. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Scorpio Tankers reported revenue of $512.73MM vs $522.75MM (down 1.92%) and analysts estimated basic earnings per share -$0.73 vs -$0.15. Analysts expect earnings to be released on November 15th, 2018. The report will be for the fiscal period ending September 30th, 2018. The reported EPS for the same quarter last year was -$0.15. The estimated EPS forecast for the next fiscal year is -$0.03 and is expected to report on February 13th, 2019.
To read the full Scorpio Tankers Inc. (STNG) report, download it here: http://MarketSourceResearch.com/register/?so=STNG
-----------------------------------------
ABOUT MARKET SOURCE RESEARCH
Market Source Research delivers the key research reports that helps serious investors, registered brokers, professional traders, and personal investment advisers find reliable information in today's markets. Market Source Research's team is comprised of financial professionals, many of which hold Chartered Financial Analyst® (CFA®) designations and FINRA® BrokerCheck® certifications. Whether identifying emerging trends, or discovering new opportunity, the team at Market Source Research is dedicated to providing accurate, informative, and objective content that's ahead of the curve. With insights on individual companies as well as sectors, readers get the industry's best available combination of big-picture perspective as well as granular detail.
REGISTERED MEMBER STATUS
Market Source Research's oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Market Source Research's roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Market Source Research have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Market Source Research's Compliance department by Phone, at +1 (704) 343-6361, or by E-mail at compliance@MarketSourceResearch.com.
LEGAL NOTICES
Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Market Source Research, Market Source Research members, and/or Market Source Research affiliates are not responsible for any gains or losses that result from the opinions expressed. Market Source Research makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Market Source Research has not been compensated for the publication of this press release by any of the above mentioned companies. Market Source Research is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.
Media Contact:
Hugo Moreau, Media Department
Office: +1 (704) 343-6361
E-mail: media@MarketSourceResearch.com
© 2018 Market Source Research. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@MarketSourceResearch.com.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.